Clinical Trials · NCT00860158
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Noah Hahn, M.D.
- Enrollment
- 1
- Start date
- Mar 2009
- Locations
- 6 sites, United States
- Primary endpoint
- To Estimate the Pathologic Complete Response (pCR) Rate